Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.60 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | F13A1 | P00488 | 1/20 | 0.54 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16900094 | 0.91 | L3MBTL1 (0.73) | L3MBTL1NPC1RAB9AHPGDKDM4E | |
| SCHEMBL18717449 | 0.86 | HDAC3 (0.56) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL10245864 | 0.85 | HPGD (0.57) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL7765076 | 0.84 | L3MBTL1 (0.79) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL10268245 | 0.83 | GAA (0.66) | L3MBTL1HPGDLMNA | |
| SCHEMBL8331572 | 0.83 | NPC1 (0.61) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL2186352 | 0.83 | HDAC2 (0.72) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL1690856 | 0.81 | HPGD (0.71) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL9011323 | 0.81 | HDAC3 (0.66) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL4074353 | 0.81 | HDAC3 (0.87) | HDAC3HDAC1HDAC2HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| US-9682955-B2 | Quinazoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-9636345-B2 | Benzimidazole derivatives useful TRPM8 channel modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-02 | — | — | US | disclosed |
| US-9617224-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | US | disclosed |
| US-20160200719-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-14 | — | — | US | disclosed |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-10 | — | — | US | disclosed |
| US-9205076-B2 | Compounds as opioid receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2015-12-08 | — | — | US | disclosed |
| US-20150150882-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL TRPM8 CHANNEL MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-04 | — | — | US | disclosed |
| US-8981113-B2 | Benzimidazole derivatives useful as TRPM8 channel modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-17 | — | — | US | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417030-B2 | Indazole peptidomimetics as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080119500-A1 | PYRIDINE IMIDAZOLES AND AZA-INDOLES AS PROGESTERONE RECEPTOR MODULATORS | JIANG WEIQIN | 2008-05-22 | — | — | US | disclosed |
| US-7375123-B2 | 1,2,4-thiadiazole derivatives as melanocortin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070004715-A1 | Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders | JANSSEN PHARMACEUTICAL, N.V., A CORP. OF BELGIUM (BE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | KCNQ1, KCNQ2, KCNJ2 | HDAC3 403/4885HDAC1 1389/4885HDAC2 819/4885 |
| US-20080119500-A1 | PYRIDINE IMIDAZOLES AND AZA-INDOLES AS PROGESTERONE RECEPTOR MODULATORS | PGR, GPER1, FSHR | HDAC3 280/4885HDAC1 317/4885HDAC2 254/4885 |
| US-20170088531-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | HDAC3 624/4885HDAC1 1245/4885HDAC2 837/4885 |
| US-20150150882-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL TRPM8 CHANNEL MODULATORS | TRPM8, TRPM4, TRPM6 | HDAC3 323/4885HDAC1 334/4885HDAC2 424/4885 |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | HDAC3 1139/4885HDAC1 461/4885HDAC2 964/4885 |
| US-20070004715-A1 | Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders | GRIN2C, GRIN2A, CHRNA2 | HDAC3 221/4885HDAC1 1251/4885HDAC2 753/4885 |
| US-20160200719-A1 | CINNOLINE DERIVATIVES USEFUL AS CB-1 RECEPTOR INVERSE AGONISTS | CNR1, CNR2, GPR119 | HDAC3 2239/4885HDAC1 3026/4885HDAC2 3483/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | HDAC3 475/4885HDAC1 553/4885HDAC2 1245/4885 |
| US-20160068512-A1 | Quinazoline Derivatives Useful as CB-1 Inverse Agonists | CNR1, CNR2, GPR119 | HDAC3 1423/4885HDAC1 2664/4885HDAC2 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.